These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'
These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'
Shares of Cara Therapeutics Inc (NASDAQ:CARA) tanked in early trading on Thursday, with the Dow shedding more than 100 points.
週四早盤，Cara Therapeutics股票（納斯達克：CARA）上演了一場大跌，道瓊斯指數下跌逾100點。
The company reported its quarterly results amid an exciting earnings season. Here are some key analyst takeaways.
在這個激動人心的業績期節，該公司公佈了季度業績。以下是一些關鍵分析師的觀點。
- Needham analyst Joseph Stringer downgraded the rating on the stock from Buy to Hold.
- HC Wainwright analyst Oren Livnat downgraded the rating on the stock from Buy to Neutral.
- 尼德姆（Needham）分析師約瑟夫·斯特林格（Joseph Stringer）將該股股票的評級從買入降級爲持有。
- HC Wainwright分析師歐倫·利夫納特（Oren Livnat）將該股票的評級從買入降級爲中立。
Check out other analyst stock ratings.
查看其他分析師的股票評級。
Needham: Cara Therapeuticssaidafter market close on Wednesday that "the dose-finding Part A portion of the Ph2/3 KOURAGE trial evaluating oral Korsuva (difelikefalin) in Notalgia Parasthetica (NP) failed to show efficacy vs. pbo," Stringer said in his downgrade note. He added that there was reportedly no evidence of any dose level showing meaningful clinical benefit versus placebo.
尼德姆分析師斯特林格在他的降級報告中表示：“Cara Therapeutics在週三收盤後表示，評估Oral Korsuva（difelikefalin）治療Notalgia Parasthetica（NP）的第二/三期KOURAGE試驗的劑量確定部分與安慰劑相比未能顯示療效。”他補充說，據報道，沒有據顯示任何劑量水平相對安慰劑表現出實質性的臨床益處。
The company plans to halt all NP program development and explore strategic alternatives, the analyst stated. There are no meaningful clinical development programs in the pipeline, he further said.
該公司計劃停止所有NP項目的開發，並探索戰略選擇，該分析師表示。他進一步表示，流水線中沒有任何實質性的臨床開發項目。
HC Wainwright: Although this was not the first clinical disappointment for oral difelikefalin, "it's particularly disappointing given earlier Phase 2 proof-of-concept data in NP was the most robust data generated by oral DFK to date," Livnat said. Following the failure of oral DFK and the company's plans to wind down or discontinue all related programs, "we see no obvious future value drivers or catalysts," he added.
HC Wainwright分析師利夫納特說：“雖然這不是口服difelikefalin的第一次臨床失望，但考慮到NP早期的二期概念證明數據是迄今爲止口服DFK產生的最強大的數據，這尤其讓人失望。”他補充道：“在口服DFK的失敗以及該公司計劃停止或終止所有相關項目之後，我們看不到明顯的未來價值驅動器或催化劑。”
"Our projected end-2Q24 cash of $60M (no debt), with burn presumably winding down, and a market cap <$40M could give CARA some strategic options including reverse merger, liquidation, or other business development," the analyst further wrote.
該分析師進一步寫道：“我們預計到2024年第二季度的現金流狀況爲6000萬美元（無債務），隨着流出預計減少，市值可能不到4億美元，這可能會給Cara Therapeutics帶來一些戰略選擇，包括逆向合併、清算或其他業務發展。”
CARA Price Action: Shares of Cara Therapeutics had declined by 34.51% to 44 cents at the time of publication on Thursday.
週四發佈時，Cara Therapeutics股價下跌34.51%，至44美分。
譯文內容由第三人軟體翻譯。